

Bassel F El-Rayes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3670026/bassel-f-el-rayes-publications-by-year.pdf>

Version: 2024-04-03

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330 papers	8,134 citations	49 h-index	79 g-index
379 ext. papers	10,001 ext. citations	4.3 avg, IF	6.03 L-index

#	Paper	IF	Citations
330	Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature.. <i>Chinese Clinical Oncology</i> , 2022 ,	2.3	
329	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.. <i>Oncology</i> , 2022 , 1-9	3.6	1
328	Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS626-TPS626	2.2	1
327	A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 563-563	2.2	
326	Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 194-194	2.2	
325	Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 4-4	2.2	
324	Correlates of financial toxicity in adult cancer patients and their informal caregivers. <i>Supportive Care in Cancer</i> , 2022 , 30, 217-225	3.9	5
323	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.. <i>Frontiers in Oncology</i> , 2022 , 12, 821903	5.3	0
322	Frontline therapy for advanced hepatocellular carcinoma: an update.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848221086126	4.7	1
321	Successful liver transplantation of recurrent fibrolamellar carcinoma following clinical and pathologic complete response to triple immunochemotherapy: A case report.. <i>Oncology Research and Treatment</i> , 2022 ,	2.8	0
320	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors.. <i>Pancreas</i> , 2021 , 50, 1382-1391	2.6	0
319	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 755113	5.3	1
318	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 74-81	2.7	9
317	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , 2021 , 11, 592351	5.3	1
316	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , 2021 , 26, 668-675	5.7	6
315	Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. <i>Pancreas</i> , 2021 , 50, 529-536	2.6	
314	Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16259-e16259	2.2	

313	Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16085-e16085	2.2	
312	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 153-160	3.8	2
311	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 3337-3348	7.4	2
310	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1836-1845	6.1	1
309	Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. <i>Annals of Surgical Oncology</i> , 2021 , 28, 97-105	3.1	2
308	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 150-160	6.1	11
307	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , 2021 , 36, 120-129	2.5	2
306	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , 2021 , 123, 596-605	2.8	1
305	Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 95-95	2.2	4
304	Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 35-35	2.2	2
303	Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 89-89	2.2	
302	Impact of primary tumor size/horizontal extent on survival in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 125-125	2.2	
301	Impact of high-risk features for stage II adenocarcinoma of the appendix. <i>Cancer Treatment and Research Communications</i> , 2021 , 27, 100329	2	1
300	Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 269-269	2.2	17
299	Epigenetics in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	10
298	Targeting KRAS in pancreatic cancer: new drugs on the horizon. <i>Cancer and Metastasis Reviews</i> , 2021 , 40, 819-835	9.6	6
297	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021 , 75, 600-609	13.4	25
296	Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G14-198).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 413-413	2.2	0

295	Impact of socioeconomic status (SES) on colorectal cancer patient survival: An analysis of 890,867 patients in the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 19-19	2.2	
294	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.. <i>Frontiers in Oncology</i> , 2021 , 11, 728076	5.3	0
293	Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. <i>Cancer</i> , 2020 , 126, 3360-3371	6.4	8
292	Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. <i>Endocrine Pathology</i> , 2020 , 31, 239-253	4.2	13
291	Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. <i>Pancreas</i> , 2020 , 49, 341-354	2.6	2
290	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 2497-2505	12.9	5
289	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020 , 49, 822-829	2.6	1
288	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020 , 25, 414-424.	4.7	6
287	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. <i>JCI Insight</i> , 2020 , 5,	9.9	12
286	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020 , 11, 1749-1757	3.3	12
285	Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 796-796	2.2	
284	Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4036-4054	5.6	3
283	Immunotherapy in Pancreatic Cancer. <i>Digestive Disease Interventions</i> , 2020 , 04, 351-357	0.2	1
282	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 660-667	3.6	7
281	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. <i>Cancer</i> , 2020 , 126, 37-45	6.4	6
280	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020 , 25, e528-e535	5.7	26
279	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1632	5.3	4
278	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, e204564	13.4	274

277	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , 2020 , 126, 4136-4147	6.4	3
276	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , 2020 , 22, 1675-1685	3.8	2
275	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , 2020 , 123, 1377-1386	8.7	1
274	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020 , 123, 1228-1234	8.7	1
273	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. <i>Surgical Oncology</i> , 2020 , 35, 460-465	2.5	
272	Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer 2020 , 8,		7
271	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , 2020 , 126, 4788-4799	6.4	6
270	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. <i>Journal of Gastrointestinal Surgery</i> , 2020 , 24, 1138-1148	3.3	3
269	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020 , 126, 575-582	6.4	24
268	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. <i>Case Reports in Oncology</i> , 2020 , 13, 239-244	1	2
267	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , 2020 , 16, 319-325	2.3	13
266	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019 , 19, 857	4.8	46
265	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 782-794	9.7	113
264	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019 , 125, 2732-2746	6.4	9
263	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , 2019 , 70, e619	13.4	4
262	Nonsurgical Management of Rectal Cancer. <i>Journal of Oncology Practice</i> , 2019 , 15, 123-131	3.1	7
261	Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , 2019 , 145, 1529-1537	7.5	28
260	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019 , 37, 1198-1206	4.3	8

259	Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. <i>Oncology</i> , 2019 , 97, 49-58	3.6	6
258	Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2019 , 6, 119-129	5.3	9
257	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2499-2511	3.8	7
256	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019 , 63, 101618	2.8	12
255	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreaticobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 944-956	2.8	9
254	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019 , 121, 809-818	8.7	92
253	Interaction of heat shock protein 90 with hypoxia inducible factor and signal transducer and activator of transcription in colon cancer. <i>Process Biochemistry</i> , 2019 , 86, 151-158	4.8	1
252	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4012-4012	2.2	136
251	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 327-327	2.2	64
250	Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 560-560	2.2	1
249	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , 2019 , 8, e11545	2	17
248	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. <i>Oncology & Hematology Review</i> , 2019 , 15, 27	0.1	1
247	Small Bowel and Appendix Cancers 2019 , 97-107		
246	Genomic alterations in appendiceal carcinoma using circulating DNA.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 658-658	2.2	
245	Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS475-TPS475	2.2	
244	Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 435-435	2.2	
243	Blood-based next-generation sequencing analysis of neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4110-4110	2.2	
242	Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15029-e15029	2.2	

241	Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15693-e15693	2.2	0
240	Perioperative therapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18231-e18231	2.2	
239	Personalized T cell therapy for metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e15183-e15183		
238	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2019 , 121, 294	2.8	3
237	Cyclooxygenase-2 in gastrointestinal malignancies. <i>Cancer</i> , 2019 , 125, 1221-1227	6.4	18
236	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 257-268	3.8	13
235	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019 , 48, 913-919	2.6	3
234	Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 331-336	2.7	4
233	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019 , 11,	6.6	13
232	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019 , 24, 911-920	5.7	19
231	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1453-1461	5.7	42
230	Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. <i>International Journal of Cancer</i> , 2019 , 145, 10-19	7.5	19
229	Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. <i>FASEB Journal</i> , 2019 , 33, 3623-3635	0.9	13
228	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , 2019 , 120, 165-171	8.7	174
227	Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. <i>Journal of Gastrointestinal Cancer</i> , 2019 , 50, 1-8	1.6	18
226	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019 , 125, 57-67	6.4	8
225	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019 , 125, 127-134	6.4	71
224	Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. <i>Journal of Gastrointestinal Cancer</i> , 2019 , 50, 269-275	1.6	3

223	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2019 , 10, 85-94	2.8	12
222	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018 , 124, 1992-2000	6.4	11
221	Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 81, 659-670	3.5	10
220	A patient-centered team approach in oncology. <i>Cancer</i> , 2018 , 124, 1856-1858	6.4	1
219	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018 , 23, 704-711	5.7	11
218	Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1026-1033	3.1	7
217	Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 126, 201-207	7	15
216	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. <i>Annals of Surgical Oncology</i> , 2018 , 25, 290-298 ^{3.1}	3.1	12
215	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018 , 124, 3118-3126	6.4	14
214	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , 2018 , 95, 138-146	3.6	5
213	Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4110-4110	2.2	10
212	Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4125-4125	2.2	1
211	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16207-e16207	2.2	1
210	Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 421-421	2.2	1
209	Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS526-TPS526	2.2	2
208	Resection of pancreatic cancer following induction chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 406-406	2.2	
207	STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 340-340	2.2	
206	Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16262-e16262	2.2	1

205	Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3604-3604 ^{2,3}		
204	Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4026-4026	2.2	
203	A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4155-TPS4155	2.2	1
202	Retrospective study of the safety of administering pegfilgrastim on the same day of 5- Fluorouracil pump disconnect.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16190-e16190	2.2	
201	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15022-e15022 ^{2,3}		
200	Molecularly Targeted Therapies in Pancreatic Cancer 2018 , 219-233		
199	Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. <i>Molecular Cancer</i> , 2018 , 17, 177	42.1	48
198	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018 , 9, 2166	8.4	63
197	Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 569-573	2.7	29
196	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2017 , 56, 288-299	5	29
195	Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , 2017 , 123, 1303-1312 ^{3,4}		70
194	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017 , 35, 718-726	2.2	49
193	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017 , 123, 3476-3485	6.4	27
192	Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. <i>Cancer Letters</i> , 2017 , 402, 110-116	9.9	16
191	Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study. <i>PLoS ONE</i> , 2017 , 12, e0177212	3.7	3
190	Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. <i>Cancer</i> , 2017 , 123, 4924-4933	6.4	15
189	Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. <i>Oncology</i> , 2017 , 93, 336-342	3.6	12
188	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017 , 22, 1107-1116	5.7	66

187	Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2017 , 30, 255-266	9.8	26
186	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. <i>Cancer</i> , 2017 , 123, 345-356	6.4	60
185	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2017 , 117, 1592-1599	8.7	59
184	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3541-3541	2.2	39
183	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4017-4017	2.2	21
182	BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4077-4077	2.2	6
181	A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4106-4106	2.2	12
180	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 235-235	2.2	2
179	Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 593-593	2.2	10
178	Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. <i>Clinical Endoscopy</i> , 2017 , 50, 491-494	2.5	2
177	Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2552-2552	2.2	
176	Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e18069-e18069	2.2	
175	Enrollment into molecular selection trials and impact on patient disposition.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14035-e14035	2.2	
174	Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15039-e15039	2.2	
173	Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4103-4103	2.2	
172	Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e15607-e15607	2.2	
171	Racial disparities in treatment and outcomes of colorectal cancer in young adults.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6559-6559	2.2	1
170	Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. <i>Modern Pathology</i> , 2016 , 29, 1575-1585	9.8	35

169	An update on the multimodality of localized rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 108, 23-32	7	5
168	Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. <i>Modern Pathology</i> , 2016 , 29, 1243-53	9.8	41
167	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 299-315	5.1	45
166	Aquaporins: Their role in gastrointestinal malignancies. <i>Cancer Letters</i> , 2016 , 373, 12-18	9.9	37
165	Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , 2016 , 52, 109-19	7.5	31
164	Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. <i>Journal of Nutritional Biochemistry</i> , 2016 , 31, 77-87	6.3	33
163	Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System[pT1: 0, pT2: >2-0, pT3: >4 cm] is More Valid and Clinically Relevant. <i>Annals of Surgical Oncology</i> , 2016 , 23, 2010-8	3.1	82
162	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , 2016 , 42, 10-7	14.4	14
161	Inhibition of NF-B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , 2016 , 373, 227-33	9.9	44
160	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016 , 21, 178-87	5.7	38
159	MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers. <i>Tumor Biology</i> , 2016 , 37, 97-104	2.9	10
158	Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3564-3564	2.2	2
157	Uridine triacetate as a life-saving antidote to capecitabine toxicity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21612-e21612	2.2	1
156	Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 655-655	2.2	1
155	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016 , 48, 596-604	5.2	20
154	A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 284-284	2.2	1
153	A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 230-230	2.2	
152	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 460-460	2.2	

151	Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21689-e21689	2.2	
150	Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15541-e15541	2.2	
149	Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21675-e21675	2.2	
148	Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4045-4045	2.2	
147	Combination of tolfenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. <i>Oncotarget</i> , 2016 , 7, 3186-200	3.3	46
146	Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. <i>Cancer</i> , 2016 , 122, 2150-7	6.4	25
145	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016 , 11, 807-814	5	2
144	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , 2016 , 24, 1150-1158	11.7	79
143	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 296-303	4	46
142	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , 2016 , 33, 48	3.7	18
141	Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. <i>International Journal of Oncology</i> , 2016 , 48, 1955-64	4.4	23
140	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , 2016 , 17, 801-810	21.7	494
139	Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. <i>International Journal of Oncology</i> , 2016 , 49, 1686-94	4.4	20
138	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. <i>Journal of Surgical Oncology</i> , 2016 , 114, 336-41	2.8	8
137	Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1167-74	4	14
136	Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. <i>Journal of Drug Targeting</i> , 2015 , 23, 257-65	5.4	5
135	First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1112-8	2.2	105
134	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , 2015 , 20, 907-14	5.7	15

133	Hypoxia inducible factor-1βIts role in colorectal carcinogenesis and metastasis. <i>Cancer Letters</i> , 2015 , 366, 11-8	9.9	80
132	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. <i>Cancer</i> , 2015 , 121, 1772-8	6.4	22
131	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2295-301	3.1	61
130	Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4392-401	3.1	25
129	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. <i>Therapeutic Advances in Medical Oncology</i> , 2015 , 7, 56-62	5.4	13
128	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2015 , 20, 981-2	5.7	22
127	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3727-32	2.2	71
126	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S276-S304	12.7	179
125	Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. <i>Cancer Letters</i> , 2015 , 357, 557-65	9.9	59
124	Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2015 , 54, 1147-58	5	59
123	Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. <i>Cancer Medicine</i> , 2015 , 4, 392-403	4.8	8
122	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. <i>Journal of Surgical Oncology</i> , 2015 , 111, 1028-34	2.8	55
121	Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 543-9	2.7	16
120	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , 2015 , 121, 2164-74	6.4	44
119	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015 , 6, 349-354	16.7	
118	Biomarkers for personalized medicine in GI cancers. <i>Molecular Aspects of Medicine</i> , 2015 , 45, 14-27	16.7	9
117	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3842-3	2.2	
116	Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging. <i>Annals of Surgical Oncology</i> , 2015 , 22 Suppl 3, S1187-95	3.1	66

115	The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine. <i>Oncology Reports</i> , 2015 , 34, 3304-10	3.5	11
114	High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 631-9	4	23
113	Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , 2015 , 35 Suppl, S224-S243	12.7	314
112	Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3596-3596	2.2	5
111	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 6613-6613	2.2	1
110	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 368-368	2.2	1
109	Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 608-608	2.2	3
108	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 658-658	2.2	1
107	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 247-53	2.8	2
106	The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 247-247	2.2	
105	Prognostic value of gender in hospitalized pancreatic patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 256-256	2.2	
104	Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4092-4092	2.2	2
103	A risk score to predict in-hospital mortality in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15256-e15256	2.2	1
102	Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17722-e17722	2.2	2
101	Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15112-e15112	2.2	
100	Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15260-e15260	2.2	
99	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. <i>Carcinogenesis</i> , 2014 , 35, 967-73	4.6	88
98	Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2014 , 25, 256-65	2.4	69

97	Targeted therapies in metastatic esophageal cancer: advances over the past decade. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 186-96	7	28
96	Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 219-25	3.8	27
95	Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review. <i>Journal of Surgical Oncology</i> , 2014 , 110, 182-96	2.8	23
94	Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2014 , 109, 556-60	2.8	9
93	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014 , 32, 682-90	4.3	8
92	Mo1135 Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States. <i>Gastroenterology</i> , 2014 , 146, S-566-S-567	13.3	3
91	Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated $\text{EGd}_2(\text{MoO}_4)_3$ mesoporous particles. <i>Dalton Transactions</i> , 2014 , 43, 3330-8	4.3	30
90	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 477-486	1	
89	HER2 in resected gastric cancer: Is there prognostic value?. <i>Journal of Surgical Oncology</i> , 2014 , 109, 61-62.8	2.8	24
88	Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. <i>American Journal of Roentgenology</i> , 2014 , 203, W706-14	5.4	43
87	Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 194-200	2.7	8
86	Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. <i>Annals of Surgery</i> , 2014 , 260, 494-501; discussion 501-3	7.8	69
85	Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases. <i>Journal of Drug Delivery</i> , 2014 , 2014, 865732	2.3	8
84	CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. <i>Cancer Research</i> , 2014 , 74, 2677-87	10.1	30
83	Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6527-6527	2.2	1
82	HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. <i>Oncotarget</i> , 2014 , 5, 9980-91	3.3	43
81	Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9626-9626	2.2	
80	Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6502-6502	2.2	

79	Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 342-342	2.2	
78	Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 528-528	2.2	
77	Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 276-276	2.2	
76	Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 308-308	2.2	
75	An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. <i>Cancer</i> , 2013 , 119, 445-53	6.4	33
74	Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. <i>Cancer</i> , 2013 , 119, 285-92	6.4	80
73	Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. <i>Cancer</i> , 2013 , 119, 454-62	6.4	27
72	Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2013 , 44, 143-51	1.6	57
71	Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 α and STAT-3. <i>Angiogenesis</i> , 2013 , 16, 903-17	10.6	58
70	Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. <i>CardioVascular and Interventional Radiology</i> , 2013 , 36, 440-8	2.7	109
69	Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1357-70	2.2	213
68	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2013 , 24, 307-14	2.4	57
67	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 88, 416-26	7	33
66	Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. <i>Pancreas</i> , 2013 , 42, 1311-5	2.6	153
65	PEGylated EGd2(MoO4)3 Mesoporous Flowers: Synthesis, Characterization, and Biological Application. <i>Crystal Growth and Design</i> , 2013 , 13, 4051-4058	3.5	28
64	Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. <i>Cancer Letters</i> , 2013 , 341, 195-203	9.9	68
63	SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. <i>Cancer Letters</i> , 2013 , 328, 10-7	9.9	23
62	In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 86, 469-76	4	47

61	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). <i>Annals of Oncology</i> , 2013 , 24, 965-73	10.3	85
60	90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 435-44	2.1	6
59	Tools to optimize the functionality of a leukemia clinical trial team. <i>Leukemia and Lymphoma</i> , 2013 , 54, 110-6	1.9	
58	Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. <i>Nutrition Reviews</i> , 2013 , 71, 562-72	6.4	55
57	Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. <i>Cancer</i> , 2013 , 119, 3148-55	6.4	73
56	Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States. <i>Cancer</i> , 2013 , 119, 4020-7	6.4	19
55	Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. <i>Cancer</i> , 2013 , 119, 3242-50	6.4	15
54	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , 2013 , 108, 762-5	8.7	20
53	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013 , 4, 308-18	2.8	35
52	Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models. <i>FASEB Journal</i> , 2013 , 27, lb572	0.9	2
51	Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 326-326	2.2	
50	Anti-angiogenic effects of curcumin and its novel analogs EF-31 and UBS-109 in colorectal cancer. <i>FASEB Journal</i> , 2013 , 27, lb574	0.9	2
49	Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15140-e15140	2.2	
48	Survival outcome of ampullary and duodenal adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14579-e14579	2.2	
47	Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14612-e14612	2.2	
46	The impact of curcumin on breast cancer. <i>Integrative Biology (United Kingdom)</i> , 2012 , 4, 996-1007	3.7	61
45	Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 224-7	3.8	15
44	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2012 , 23, 1286-93.e1	2.4	22

43	Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 707-18	6.4	4
42	Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis 2012 ,		6
41	Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. <i>Anticancer Research</i> , 2012 , 32, 3559-63	2.3	6
40	An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 206-206	2.2	
39	Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14512-e14512	2.2	
38	Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. <i>Annals of Surgical Oncology</i> , 2011 , 18, 2699-705	3.1	35
37	Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3384-90	3.1	18
36	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011 , 29, 694-9	4.3	42
35	Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 135-9	2.7	10
34	CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 98-105	1.9	30
33	A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. <i>Annals of Oncology</i> , 2010 , 21, 1999-2004	10.3	80
32	Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. <i>Pancreas</i> , 2010 , 39, 967-71	2.6	15
31	Clinicopathological analysis of primary epithelial appendiceal neoplasms. <i>Medical Oncology</i> , 2010 , 27, 1073-8	3.7	8
30	Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2010 , 110, 171-81	4.7	21
29	Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. <i>Case Reports in Oncology</i> , 2009 , 2, 220-228	1	1
28	Exploitation of protein kinase C: a useful target for cancer therapy. <i>Cancer Treatment Reviews</i> , 2009 , 35, 1-8	14.4	94
27	Protein kinases C isozymes are differentially expressed in human breast carcinomas. <i>Life Sciences</i> , 2009 , 84, 766-71	6.8	9
26	Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1708-19	6.1	75

25	Protein kinase C: a target for therapy in pancreatic cancer. <i>Pancreas</i> , 2008 , 36, 346-52	2.6	26
24	Small molecule tyrosine kinase inhibitors in pancreatic cancer. <i>Biologics: Targets and Therapy</i> , 2008 , 2, 707-15	4.4	13
23	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 283-9	3.5	17
22	A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 101-5	2.7	0
21	A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007 , 30, 340-5	2.7	21
20	Potential of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. <i>Cancer Research</i> , 2006 , 66, 10553-9	10.1	116
19	Phase I study of bryostatin 1 and gemcitabine. <i>Clinical Cancer Research</i> , 2006 , 12, 7059-62	12.9	20
18	A phase I study of flavopiridol and docetaxel. <i>Investigational New Drugs</i> , 2006 , 24, 305-10	4.3	22
17	A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005 , 28, 152-6	2.7	23
16	Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. <i>Investigational New Drugs</i> , 2005 , 23, 57-62	4.3	9
15	A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2005 , 23, 583-90	4.3	80
14	Cellular DNA content parameters as prognostic indicators in human astrocytomas. <i>Journal of Neuro-Oncology</i> , 2005 , 71, 85-9	4.8	5
13	Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 25-31	4.4	16
12	Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1943-51	6.1	58
11	Cytochrome p450 and glutathione transferase expression in squamous cell cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 4412-6	12.9	10
10	Targeting the epidermal growth factor receptor. <i>British Journal of Cancer</i> , 2004 , 91, 418-24	8.7	126
9	A phase II study of carboplatin and paclitaxel in esophageal cancer. <i>Annals of Oncology</i> , 2004 , 15, 960-5	10.3	39
8	Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. <i>Breast Cancer Research and Treatment</i> , 2004 , 83, 189-189	4.4	

7	Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. <i>Pancreas</i> , 2004 , 28, e90-5	2.6	102
6	Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2920-5	2.2	46
5	Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy. <i>American Journal of Hematology</i> , 2003 , 72, 154	7.1	4
4	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , 2003 , 61, 774-80	1.6	98
3	Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck. <i>Otolaryngology - Head and Neck Surgery</i> , 2003 , 128, 169-77	5.5	2
2	Developments in the systemic therapy of pancreatic cancer. <i>Cancer Investigation</i> , 2003 , 21, 73-86	2.1	29
1	Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy. <i>Breast Cancer Research and Treatment</i> , 2002 , 76, 111-6	4.4	24